Publications by Tone Ikdahl
30 publications found
Original articles
Dynamics of magnetization at infinite temperature in a Heisenberg spin chain
Science, 384 (6691), 48-53
DOI 10.1126/science.adi7877, PubMed 38574139
Stable quantum-correlated many-body states through engineered dissipation
Science, 383 (6689), 1332-1337
DOI 10.1126/science.adh9932, PubMed 38513021
Formation of robust bound states of interacting microwave photons
Nature, 612 (7939), 240-245
DOI 10.1038/s41586-022-05348-y, PubMed 36477133
Noise-resilient edge modes on a chain of superconducting qubits
Science, 378 (6621), 785-790
DOI 10.1126/science.abq5769, PubMed 36395220
Feasibility of a physical activity intervention during and shortly after chemotherapy for testicular cancer
BMC Res Notes, 10 (1), 214
DOI 10.1186/s13104-017-2531-y, PubMed 28619116
Magnetic resonance spectroscopy of an atomically thin material using a single-spin qubit
Science, 355 (6324), 503-507
DOI 10.1126/science.aal2538, PubMed 28104795
Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
Oncotarget, 7 (46), 75013-75022
DOI 10.18632/oncotarget.12601, PubMed 27738330
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer
Oncotarget, 7 (37), 59441-59457
DOI 10.18632/oncotarget.11118, PubMed 27509063
The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma
Cancer Res, 76 (17), 5092-102
DOI 10.1158/0008-5472.CAN-16-0658, PubMed 27488532
Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
Oncotarget, 7 (27), 41948-41958
DOI 10.18632/oncotarget.9632, PubMed 27248825
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
Pharmacogenomics J, 16 (3), 272-9
DOI 10.1038/tpj.2015.54, PubMed 26261061
Comparing two classifications of cancer cachexia and their association with survival in patients with unresected pancreatic cancer
Nutr Cancer, 67 (3), 472-80
DOI 10.1080/01635581.2015.1004728, PubMed 25710201
Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas
Mol Oncol, 9 (4), 758-71
DOI 10.1016/j.molonc.2014.12.002, PubMed 25579086
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
BMC Cancer, 14, 340
DOI 10.1186/1471-2407-14-340, PubMed 24884501
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
PLoS One, 9 (2), e87746
DOI 10.1371/journal.pone.0087746, PubMed 24498368
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity
J Clin Oncol, 31 (35), 4453-61
DOI 10.1200/JCO.2013.51.0826, PubMed 24220555
Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment
Mol Oncol, 8 (1), 59-67
DOI 10.1016/j.molonc.2013.09.001, PubMed 24119443
Opportunities of improvement in the management of pancreatic and periampullary tumors
Scand J Gastroenterol, 48 (5), 617-25
DOI 10.3109/00365521.2013.781218, PubMed 23597153
Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival
Eur J Surg Oncol, 39 (6), 559-66
DOI 10.1016/j.ejso.2013.02.020, PubMed 23498362
Improved survival and quality of life in patients undergoing R1 pancreatic resection compared to patients with locally advanced unresectable pancreatic adenocarcinoma
Pancreatology, 13 (2), 180-5
DOI 10.1016/j.pan.2013.01.003, PubMed 23561977
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
BMC Cancer, 12, 534
DOI 10.1186/1471-2407-12-534, PubMed 23167843
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
J Clin Oncol, 30 (15), 1755-62
DOI 10.1200/JCO.2011.38.0915, PubMed 22473155
Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing
PLoS One, 7 (4), e34150
DOI 10.1371/journal.pone.0034150, PubMed 22529906
Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations
Diagn Mol Pathol, 20 (3), 158-65
DOI 10.1097/PDM.0b013e31820b49e2, PubMed 21817902
The level of claudin-7 is reduced as an early event in colorectal carcinogenesis
BMC Cancer, 11, 65
DOI 10.1186/1471-2407-11-65, PubMed 21310043
Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma
BMC Cancer, 7, 192
DOI 10.1186/1471-2407-7-192, PubMed 17935612
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Breast Cancer Res, 9 (3), R30
DOI 10.1186/bcr1675, PubMed 17504517
Review articles
Genetic variants associated with cisplatin-induced ototoxicity
Pharmacogenomics, 9 (10), 1521-30
DOI 10.2217/14622416.9.10.1521, PubMed 18855538
Other articles
KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem
Expert Rev Mol Diagn, 12 (4), 327-8
DOI 10.1586/erm.12.29, PubMed 22616697
Concurrent mediastinal germ-cell tumour and haematological malignancy: case report and short review of literature
Acta Oncol, 47 (3), 466-9
DOI 10.1080/02841860701636272, PubMed 18348004